2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

322. Hemophilia A and B: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Gene Therapy, Women’s Health, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Systems-Based Hematology, Diseases, Bleeding and Clotting, Hemophilia, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

3040 Characterizing residual joint bleeds in patients achieving target joint resolution on emicizumab: A pooled post hoc analysis of HAVEN 1–4 and stasey

Steven Pipe, MD, Magdalena Lewandowska, MD2, Eunice Tzeng, PharmD3, Ling Gao4, Lucy Lee, PharmD5, Mark T. Reding, MD6
1 University of Michigan, Ann Arbor, United States
2 Innovative Hematology/Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States
3 Genentech, Inc., South San Francisco, California, United States
4 Analystat Corporation, Petersburg, Washington, United States
5 Genentech, Inc., South San Francisco, California, United States
6 University of Minnesota, Minneapolis, Minnesota, United States

Background: People with hemophilia A (PwHA) have a deficiency of coagulation factor (F)VIII, resulting in recurrent bleeding, which leads to progressive joint damage. Joint bleeds were reduced in the HAVEN 1–4 trials of emicizumab (Callaghan, Blood 2021). However, as any joint bleed has the potential to contribute to irreversible joint damage (Gualtierotti, J Thromb Haemost 2021), there is a need to characterize bleeding that may still occur in resolved target joints. Here, data from participants with/without FVIII inhibitors enrolled in the Phase III HAVEN 1, HAVEN 2, HAVEN 3, HAVEN 4, or STASEY studies (NCT02622321, NCT02795767, NCT02847637, NCT03020160, NCT03191799) were pooled to characterize residual joint bleeds in PwHA achieving target joint resolution on emicizumab prophylaxis.

Methods: Data from participants in HAVEN 1–4 or STASEY were pooled for this post hoc analysis. Participants were included if they had target joints at baseline and received ≥1 year of emicizumab prophylaxis. Analyses were performed annually from the 1st to 5th year of emicizumab treatment. Target joints were defined as those with ≥3 bleeds in 6 months. Target joint resolution was defined as ≤2 spontaneous or traumatic bleeds during a 1-year period in a previously defined target joint. A new bleed was defined as a bleed at a new location or a bleed 72 hours after the last treatment at the same location. Target joints were characterized by number and location. Target joint bleeds were characterized by bleed type, treatment, participant subgroup, and annualized bleeding rate (ABR). Participant subgroups included emicizumab dosing regimen, age at baseline, FVIII inhibitor status at baseline, and treatment in the 24 weeks prior to study entry.

Results: At baseline, 347/592 participants had ≥1 target joints and were included in the analysis. Greater proportions of adolescents and adults (≥12 years) had target joints (316/507 [62.3%]) compared with pediatric (1 to <12 years) participants (31/85 [36.5%]).

During the 1st year of emicizumab treatment, 250/347 (72.0%) participants had no bleeds in target joints. Of the 890 target joints present at baseline, 96.6% (860/890) were resolved during the 1st year; 86.1% (766/890) had no bleeds, 8.4% (75/890) had 1 bleed, and 2.1% (19/890) had 2 bleeds. Most participants (291/347 [83.9%]) had no treated bleeds in target joints. Among the 69/890 (7.8%) target joints with treated bleeds, 78.3% (54/69) joints had ≤2 bleeds and 21.7% (15/69) joints had ≥3 bleeds. Of 74 bleeds in the 15 target joints with ≥3 treated bleeds, 79.7% (59/74) of bleeds were traumatic. Target joint bleeds were treated with standard half-life (SHL) FVIII (70.1% [96/137]), extended half-life (EHL) FVIII (7.3% [10/137]), recombinant activated FVII (19.7% [27/137]), and activated prothrombin complex concentrate (6.6% [9/137]); a bleed could be treated by more than one medication. The median ABR (interquartile range [IQR]) for treated target joint bleeds during the 1st year of emicizumab treatment was 0 (0). Target joint resolution and ABRs were similar across participants, irrespective of emicizumab dosing regimen, age, FVIII inhibitor status, and prior treatment.

During the 2nd, 3rd, 4th, and 5th year of emicizumab treatment, 186/212 (87.7%), 102/123 (82.9%), 76/91 (83.5%), and 55/65 (84.6%) participants had no treated bleeds in target joints, respectively. The proportion of target joints with 1 or 2 treated bleeds was 79.4% (27/34), 86.2% (25/29), 80.8% (21/26), and 78.6% (11/14) during the 2nd to 5th year, respectively. Of target joints with ≥3 treated bleeds, the proportion of bleeds that were traumatic were 86.7% (26/30), 92.9% (13/14), 85.7% (48/56), and 77.8% (7/9), during the 2nd to 5th year, respectively. After the 2nd year of emicizumab, all target joint bleeds were treated with SHL or EHL FVIII. The median (IQR) ABR for treated target joint bleeds was 0 (0) at all yearly timepoints from the 2nd year.

Conclusions: In long-term follow-up, emicizumab treatment resulted in high rates of both target joint resolution and zero treated target joint bleeds across participants in the HAVEN 1–4 and STASEY studies, irrespective of dosing regimen, age, inhibitor status, and prior treatment. Most bleeds occurring in resolved target joints were traumatic and were treated. These findings support efforts to characterize target joint resolution and prevent residual bleeding, thus reducing a key driver of hemophilic arthropathy.

Steven Pipe, MD: Equilibra Bioscience - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); Werfen - Consultancy (Includes expert testimony); CSL Behring - Consultancy (Includes expert testimony); BioMarin - Consultancy (Includes expert testimony); Roche/Genentech/Spark Therapeutics - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Bayer - Consultancy (Includes expert testimony); Chugai - Consultancy (Includes expert testimony); HEMA Biologics - Consultancy (Includes expert testimony); LFB - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); GeneVentiv - Consultancy (Includes expert testimony); Star Therapeutics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Metagenomi - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Inovio - Consultancy (Includes expert testimony)